Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloNK
- Development stage
- Phase 2
- Lead developer
- Artiva Biotherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AlloNK (AB-101) is an off-the-shelf, allogeneic, non-genetically modified natural killer (NK) cell therapy developed by Artiva Biotherapeutics. Derived from umbilical cord blood and cryopreserved for on-demand use, AlloNK is designed to enhance antibody-dependent cellular cytotoxicity (ADCC) when administered in combination with monoclonal antibodies. By leveraging the innate power of NK cells to recognize and destroy target cells, particularly those opsonized by antibodies, AlloNK aims to treat B-cell malignancies and autoimmune diseases such as systemic lupus erythematosus (SLE). Its manufacturing process allows for large-scale production and consistent potency across batches, providing a scalable alternative to autologous cell therapies.
- Brand names
- AlloNK
- Other names
- AB-101AB101AB 101allogeneic NK cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on AlloNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloNK.